Related Experiment Video
Updated: Jul 12, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Effect of single mannitol bolus in intracerebral hemorrhage
U K Misra1, J Kalita, A Vajpayee
1Department of Neurology, Sanjay Ghandi PGIMS, Lucknow, India. ukmisra@sgpgi.ac.in
Insights
This study investigated mannitol for intracerebral hemorrhage (ICH). Mannitol showed transient clinical improvement in some patients but did not significantly reduce hematoma or edema in the short term.
Area of Science:
- Neurosurgery
- Neurology
- Clinical Trials
Background:
- Controversy exists regarding mannitol's efficacy in intracerebral hemorrhage (ICH).
- Limited data available on single mannitol bolus administration in ICH patients with significant midline shift.
Purpose of the Study:
- To explore the effects of a single mannitol bolus in patients with supratentorial ICH and midline shift.
- To assess clinical outcomes and radiological changes following mannitol administration.
Main Methods:
- Open-label, randomized trial with blinded outcome assessment.
- Inclusion criteria: CT-proven primary supratentorial ICH with midline shift ≥3 mm.
- Intervention: Single 20% mannitol bolus (1.5 g/kg) vs. control.
- Outcome measures: Clinical scales (GCS, CNS), pupillary response, breathing, posturing, pyramidal signs, MRI (horizontal shift, SSS-PMJ distance, edema).
Main Results:
- No significant baseline differences in demographics or clinical/radiological parameters between mannitol and control groups.
- Transient clinical improvement observed in 5/12 mannitol-treated patients, lasting 30-60 minutes.
- No significant changes in horizontal shift or SSS-PMJ distance at 30 or 60 minutes post-mannitol.
- No significant difference in the change of horizontal shift or SSS-PMJ distance between groups.
Conclusions:
- Single mannitol bolus may offer transient clinical benefits in ICH patients with midline shift.
- Mannitol did not demonstrate significant short-term reduction in hematoma or edema-related measures.
- Further research is needed to clarify the role and optimal use of mannitol in ICH management.
Abstract:
Because of existing controversy about use of mannitol in intracerebral hemorrhage (ICH) this open exploratory trial with blinded outcome assessment of single mannitol bolus in ICH was undertaken. CT proven primary supratentorial ICH patients having midline shift of > or =3 mm were randomized into 20% mannitol (1.5 g/kg) and control groups. Clinical evaluation included Glasgow coma scale (GCS) score, Canadian Neurological scale (CNS) score, pupils, breathing, extensor posturing and contra-lateral pyramidal signs. On cranial MRI horizontal (HS), superior sagittal sinus to pontomesencephalic junction (SSS-PMJ) distance and edema hematoma complex were measured. Twelve patients each were in mannitol and control groups. The age, sex, GCS score, CNS score, pupillary asymmetry, contra-lateral pyramidal signs, HS and SSS-PMJ distance in mannitol and control groups did not differ significantly. Mannitol infusion resulted clinical improvement in five patients, which lasted for 30-60 min. HS and SSS-PMJ distance in mannitol and control groups did not change at 30 or 60 min from the baseline. The change in HS and SSS-PMJ distance were also not significantly different between the two groups both at 30 and 60 min. Mannitol led to transient clinical improvement in five patients without significant reduction in HS or SSS-PMJ distance at 30 and 60 min.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Increased Intracranial Pressure l: Introduction
Cerebral Edema l: Introduction
